Keywords: baycol, withdrawal, blow, bayer, little, impact, global
Baycol withdrawal: "blow for Bayer but little impact on global statins
Article | 10 August 2001
Last week's withdrawal from the market of Bayer's cholesterol lowererBaycol/Lipobay (cerivastatin; Marketletter August 13) may have come as a great ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
